Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals Limited announced that the FDA has accepted the Biologics License Application for TLX250-CDx, a novel imaging agent for kidney cancer, granting it a Priority Review. This development positions Telix to potentially launch the first imaging agent capable of accurately diagnosing clear cell renal cell carcinoma, enhancing the company’s standing in precision medicine and potentially transforming kidney cancer management.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, the company operates internationally, with a focus on addressing significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: 42.51%
Average Trading Volume: 4,631
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.48B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.